glp 1 agonist therapy Five Unexpected New Uses for GLP-1 Receptor Agonists Metabolic Flux Adaptations During GLP-1

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens

Further studies are required to clarify the differences in their effects on the kidney and how to use them appropriately in clinical practice

[DOI] [PMC free article] [PubMed] [Google Scholar] 3.GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

17 Patients should discuss with their providers strategies to improve glucose control such as taking insulin more often, changing the type of insulin they use, taking insulin after meals instead of before, or checking blood glucose levels more frequently after eating to determine when insulin admin-istration is necessary

The growing health awareness and presence of robust healthcare systems are increasing accessibility, where companies are collaborating to develop their new formulations

This decline may be due to the decreased GLP-1 secretion or impairment of L-cell development [15,16,17,18]